Navigation Links
Research points to way to improve heart treatment
Date:3/10/2010

Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects. New basic science findings from a University of Iowa study suggest a way that treatments could potentially be refined so that they work better and target only key heart-related mechanisms.

The team, which included researchers from Vanderbilt University, showed in theory that it might be possible to use drugs that maintain the positive effects on heart function of a known enzyme called calmodulin kinase II (CaM kinase) while reducing its negative effects. The findings were published the week of March 1 in the Early Online Edition of the Proceedings of the National Academy of Sciences.

anderson"CaM kinase helps regulate calcium, which is essential to heart function, but CaM kinase's calcium connection also can play a role in electrical problems that lead to irregular heart beats and cell death. This new finding suggests a specific way to keep the wanted CaM kinase effects but at the same time eliminate the bad effects," said Mark E. Anderson, M.D., Ph.D., professor and head of internal medicine at the University of Iowa Roy J. and Lucille A. Carver College of Medicine.

Anderson said that heart failure is among the most common discharge diagnoses for patients leaving hospital. "Most patients with heart failure are at risk of sudden death. Figuring out how and why heart failure happens is a major goal for academic medicine," Anderson said.

CaM kinase adds phosphate groups to other proteins -- a process known as phosphorylation. This process can activate proteins and set in motion or sustain cell activity.

"The study showed, surprisingly, the importance of CaM kinase's effect on two particular amino acid targets among the thousands of amino acids that make up protein targets for phosphorylation by CaM kinase. Controlling these targets might prevent the 'ripple effect' of other molecular
'/>"/>

Contact: Becky Soglin
becky-soglin@uiowa.edu
319-356-7127
University of Iowa
Source:Eurekalert

Page: 1 2

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Newly created cancer stem cells could aid breast cancer research
3. Dominant cholesterol-metabolism ideas challenged by new research
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. U of MN researchers discover noninvasive diagnostic tool for brain diseases
10. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
11. Story ideas from the Journal of Lipid Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... as part of her undergraduate degree (MSci in Palaeontology and ... evolved in a most unusual way, becoming more and more ... is published today in the Journal of Systematic Palaeontology ... plants evolves, they quickly try out all the options. ...
... the Georgia Institute of Technology have designed a multiple-compartment ... drugs of different types. The researchers used a simple ... less than one micron. The capsule,s structure -- ... of the shell -- provides spatially-segregated compartments that make ...
... mapping various genomes onto an X-Y axis, a team comprised ... Darwin and a fruit fly -- among other organisms -- ... Size in Diploid Eukaryotic Species Centers on the Average Length ... Molecular Biology and Evolution . It details a project ...
Cached Biology News:The rise and rise of the flying reptiles 2Unique gel capsule structure enables co-delivery of different types of drugs 2Discovering the bigger picture in chromosomes 2Discovering the bigger picture in chromosomes 3
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... SAN DIEGO , Dec. 22, 2014 ... that the Decipher Prostate Cancer Classifier, a genomic test ... disease in node-negative, high-risk men managed by radical prostatectomy ... with radical prostatectomy is relatively uncommon, using tumor genomics ... form of metastatic disease is an important advance. The ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ITRA Global, ... and occupiers of commercial real estate, has further expanded ... offices in Perth and Brisbane, Western Australia, reports Mylinda ... directors. , ITRA Global / ACORPP (Australian Corporate ... independent consultancy company providing property services to a wide ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... CITY, China, July 2 /Xinhua-PRNewswire-FirstCall/,-- China Pharma Holdings, ... manufactures, and markets generic and branded bio-,pharmaceutical products ... at the Collins Stewart Fourth Annual Growth Conference ... conference is being held at the Mandarin,Oriental Hotel ...
... cells manufactured from bone marrow; SV ... SALT LAKE CITY and HAMBURG, Germany, July 2 ... cell therapies,for the treatment of acute kidney injury, today ... round was led by SV Life Sciences with Novo,A/S ...
... MELBOURNE, Australia, July 2 Research conducted ... has contributed significantly to a,major licensing agreement ... Germany-based pharmaceutical company, Merck,Serono., Under the ... seek,to develop new treatments for multiple sclerosis ...
Cached Biology Technology:China Pharma Holdings, Inc. to Present at Collins Stewart Fourth Annual Growth Conference in New York on July 8, 2008 at 2:00 p.m. EDT 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2
... an ~185 kDa protein, corresponding to the ... tyrosine 1248 on SDS-PAGE immunoblots. The affinity ... the non-phosphorylated peptide to remove antibodies that ... protein. In cell lines where EGFR ...
... Cyclin D2 is a G1 cyclin required ... candidate for a proto-oncogene. cyclin D2 ... and/or cdk6. Species Reactivity: Human, Mouse, ... DCS-3.1 MAb is particularly well suited for ...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... Immunogen: ... acids 22-37 SGHKSEEKREKMKRTL Antigen ... G-protein signalling; Antigen Subfamily: ... G-protein signalling Recommended Storage: ...
Biology Products: